Research
Hormonal
SGLT2 inhibitors (e.g., Dapagliflozin, Ipragliflozin) and GLP-1 agonists (e.g., Exenatide) improve endothelial function in T2DM patients, independent of or beyond their glucose-lowering effects.
If you have T2DM, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs not only lower blood sugar but also directly protect your blood vessels and heart, improving how your arteries expand and contract.
GoodSupportsHIGH confidence
Ipragliflozin (a novel selective sodium–glucose cotransporter 2 (SGLT2) Inhibitor) has been shown to improve hyperglycemia and prevent the development of endothelial dysfunction... acute administration of dapagliflozin resulted into significantly improved systemic endothelial function... continuous intravenous infusion of glucagon-like peptide-1 (GLP-1) analogs was reported to improve the blood glucose-independent vascular endothelial dysfunction in T2DM patients with stable CAD.
Why this rating
Supported by multiple studies cited in the review, including clinical trials on specific drugs.
Source
Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies
Raminderjit Kaur et al. · Cardiovascular Diabetology · 2018
DOI 10.1186/s12933-018-0763-3
narrative_reviewCited 726×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →